Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Reaches New 12-Month High – Here’s What Happened

Shares of Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) hit a new 52-week high during trading on Monday . The company traded as high as $52.25 and last traded at $52.25, with a volume of 0 shares trading hands. The stock had previously closed at $52.25.

Analyst Ratings Changes

Separately, Royal Bank of Canada raised Recordati Industria Chimica e Farmaceutica to a “hold” rating in a report on Monday, October 7th.

Recordati Industria Chimica e Farmaceutica Stock Performance

The firm’s fifty day moving average price is $52.25 and its 200-day moving average price is $51.86. The company has a market cap of $10.78 billion, a price-to-earnings ratio of 26.13 and a beta of 0.33. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.36 and a quick ratio of 0.95.

Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) last posted its earnings results on Tuesday, July 30th. The company reported $0.70 earnings per share (EPS) for the quarter. Recordati Industria Chimica e Farmaceutica had a net margin of 17.41% and a return on equity of 30.78%. The firm had revenue of $622.00 million during the quarter.

Recordati Industria Chimica e Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.